Role of Routine Nasogastric Decompression After Subtotal Gastrectomy - Full Text View

Sponsored by:	Chinese University of Hong Kong
Information provided by:	Chinese University of Hong Kong
ClinicalTrials.gov Identifier:	NCT00164918

Purpose

The aim of the study is to evaluate whether subtotal gastrectomy without post-operative nasogastric decompression is better in terms of early post-operative bowel function and chest complication.

Condition	Intervention	Phase
Cancer of Stomach	Device: nasogastric tube	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Role of Routine Nasogastric Decompression After Subtotal Gastrectomy

Resource links provided by NLM:

MedlinePlus related topics: Cancer Stomach Cancer

U.S. FDA Resources

Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:

Bowel function and related symptoms early post-op

Estimated Enrollment:	90
Study Start Date:	September 2004

Detailed Description:

Nasogastric decompression is an intra-operative routine in most of the time to facilitate exposure of operative field during elective subtotal gastrectomy, but whether it should be retained post-operatively is controversial. Nasogastric decompression helps to drain the gastric remnant in case there is edema around the gastrojejunostomy, ileus and delayed gastric emptying, which can theoretically relieve nausea and abdominal distension.

Besides, it may help decrease diaphragmatic splintage and hence decrease chance of chest infection if ileus occurs. However, nasogastric intubation could cause patient discomfort; also it has been shown that it would cause gastroesophageal reflux which may be associated with chest complication.

There have been studies showing that routine post-operative nasogastric decompression is not necessary for gastrectomy in general, but the role in subtotal gastrectomy for stomach cancer is not well defined.

Eligibility

Ages Eligible for Study:	18 Weeks and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:All patients suffering from carcinoma of stomach, decided for operation

subtotal, D1/D2 dissection
palliative resection

Exclusion Criteria:

actively bleeding tumor
perforation of tumor
patient present with gastric outlet obstruction
combine organ excision
known diabetes with nephropathy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00164918

Contacts

Contact: Enders K. W. Ng, MD	85226322627	endersng@surgery.cuhk.edu.hk
Contact: Man Yee Yung, BN	85226322956	myyung@surgery.cuhk.edu.hk

Locations

China
Surgical Ward, Prince of Wales Hospital	Recruiting
Hong Kong, China
Contact: Enders K.W. Ng, MD 85226322627 endersng@surgery.cuhk.edu.hk
Contact: Man Yee Yung, BN 85226322956 myyung@surgery.cuhk.edu.hk
Sub-Investigator: Chris K.W. Yau, MRCS (Ed)
Principal Investigator: Enders K.W. Ng, MD

Sponsors and Collaborators

Chinese University of Hong Kong

Investigators

Principal Investigator:

Enders K.W. Ng, MD

Chinese University of Hong Kong

More Information

No publications provided

Study ID Numbers:	CRE-2004.311
Study First Received:	September 12, 2005
Last Updated:	September 12, 2005
ClinicalTrials.gov Identifier:	NCT00164918 History of Changes
Health Authority:	Hong Kong: Department of Health

Study placed in the following topic categories:

Stomach Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases

Stomach Neoplasms
Gastrointestinal Neoplasms
Stomach Cancer

Additional relevant MeSH terms:

Neoplasms
Stomach Diseases
Digestive System Diseases
Neoplasms by Site

Digestive System Neoplasms
Gastrointestinal Diseases
Stomach Neoplasms
Gastrointestinal Neoplasms

ClinicalTrials.gov processed this record on July 06, 2009